The synthesis and pharmacological evaluation of adamantane-derived indoles: Cannabimimetic drugs of abuse

ACS Chemical Neuroscience

Volumn 4, Issue 7, 2013, Pages 1081-1092

  Banister, Samuel D ^a,b   Wilkinson, Shane M ^a   Longworth, Mitchell ^a   Stuart, Jordyn ^c   Apetz, Nadine ^b   English, Katrina ^b   Brooker, Lance ^d   Goebel, Catrin ^d   Hibbs, David E ^b   Glass, Michelle ^e   Connor, Mark ^c   McGregor, Iain S ^b   Kassiou, Michael ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

^d NATIONAL MEASUREMENT INSTITUTE   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

9 tetrahydrocannabinol; AB 001; cannabinoid receptor; drug abuse; indole

Indexed keywords

AB 001; AB 002; ADAMANTAN 1 YL(1 PENTYL 1 H INDOLE 3 CARBOXAMIDE; ADAMANTANE DERIVATIVE; BAPINEUZUMAB; INDOLE DERIVATIVE; N (ADAMTAN 1 YL) 1 PENTYL 1H INDOLE 3 CARBOXAMIDE; SDB 001; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ARTICLE; BODY TEMPERATURE; BRADYCARDIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SYNTHESIS; HEART RATE; HUMAN; HYPOTHERMIA; IN VITRO STUDY; IN VIVO STUDY; INDUCED HYPOTHERMIA; MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

ADAMANTANE; ANIMALS; BODY TEMPERATURE; CANNABINOIDS; HEART RATE; HUMANS; INDOLES; MICE; RATS;

EID: 84880350445     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400035r     Document Type: Article

References (81)

1. Howlett, A. C., Barth, F., Bonner, T. I., Cabral, G., Casellas, P., Devane, W. A., Felder, C. C., Herkenham, M., Mackie, K., Martin, B. R., Mechoulam, R., and Pertwee, R. G. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors Pharmacol. Rev. 54, 161-202
2. Mackie, K. (2008) Cannabinoid receptors: Where they are and what they do J. Neuroendocrinol. 20, 10-14
3. Gaoni, Y. and Mechoulam, R. (1964) Isolation, structure, and partial synthesis of an active constituent of hashish J. Am. Chem. Soc. 86, 1646-1647
4. Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., Mechoulam, R., and Ross, R. A. (2010) International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2 Pharmacol. Rev. 62, 588-631
5. UNODC. UNODC, World Drug Report 2011 (United Nations Publication, Sales No. E.11.XI.10).
6. Zuardi, A. W. (2006) History of cannabis as a medicine: A review Rev. Bras. Psiquiatr. 28, 153-157
7. Pertwee, R. (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids AAPS J. 7, E625-E654
8. Mackie, K. (2006) Cannabinoid receptors as therapeutic targets Annu. Rev. Pharmacol. Toxicol. 46, 101-122
9. Bellocchio, L., Mancini, G., Vicennati, V., Pasquali, R., and Pagotto, U. (2006) Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases Curr. Opin. Pharmacol. 6, 586-591
10. Guindon, J. and Hohmann, A. G. (2008) Cannabinoid CB2 receptors: A therapeutic target for the treatment of inflammatory and neuropathic pain Br. J. Pharmacol. 153, 319-334
11. Janero, D. R. and Makriyannis, A. (2009) Cannabinoid receptor antagonists: Pharmacological opportunities, clinical experience, and translational prognosis Expert Opin. Emerging Drugs 14, 43-65
12. Oesch, S. and Gertsch, J. (2009) Cannabinoid receptor ligands as potential anticancer agents-high hopes for new therapies? J. Pharm. Pharmacol. 61, 839-853
13. Turcotte, D., Dorze, J.-A. L., Esfahani, F., Frost, E., Gomori, A., and Namaka, M. (2010) Examining the roles of cannabinoids in pain and other therapeutic indications: A review Expert Opin. Pharmacother. 11, 17-31
14. 9- tetrahydrocannabinol and cannabidiol Tetrahedron Lett. 54, 52-54
15. Weissman, A., Milne, G. M., and Melvin, L. S. (1982) Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol J. Pharmacol. Exp. Ther. 223, 516-523
16. D'Ambra, T. E., Estep, K. G., Bell, M. R., Eissenstat, M. A., Josef, K. A., Ward, S. J., Haycock, D. A., Baizman, E. R., and Casiano, F. M. (1992) Conformationally restrained analogs of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor J. Med. Chem. 35, 124-135
17. Huffman, J. W., Dai, D., Martin, B. R., and Compton, D. R. (1994) Design, synthesis and pharmacology of cannabimimetic indoles Bioorg. Med. Chem. Lett. 4, 563-566
18. Wiley, J. L., Compton, D. R., Dai, D., Lainton, J. A. H., Phillips, M., Huffman, J. W., and Martin, B. R. (1998) Structure-activity relationships of indole- and pyrrole-derived cannabinoids J. Pharmacol. Exp. Ther. 285, 995-1004
19. Aung, M. M., Griffin, G., Huffman, J. W., Wu, M.-J., Keel, C., Yang, B., Showalter, V. M., Abood, M. E., and Martin, B. R. (2000) Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB1 and CB2 receptor binding Drug Alcohol Depend. 60, 133-140
20. Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., and Ferreirós, N. (2009) 'Spice' and other herbal blends: Harmless incense or cannabinoid designer drugs? J. Mass Spectrom. 44, 832-837
21. Vardakou, I., Pistos, C., and Spiliopoulou, C. (2010) Spice drugs as a new trend: Mode of action, identification and legislation Toxicol. Lett. 197, 157-162
22. Fattore, L. and Fratta, W. (2011) Beyond THC: The new generation of cannabinoid designer drugs Front. Behav. Neurosci. 5, 60
23. Barratt, M. J., Cakic, V., and Lenton, S. (2012) Patterns of synthetic cannabinoid use in Australia Drug Alcohol Rev. 32, 141-146
24. Lapoint, J., James, L. P., Moran, C. L., Nelson, L. S., Hoffman, R. S., and Moran, J. H. (2011) Severe toxicity following synthetic cannabinoid ingestion Clin. Toxicol. 49, 760-764
25. Mir, A., Obafemi, A., Young, A., and Kane, C. (2011) Myocardial infarction associated with use of the synthetic cannabinoid K2 Pediatrics 128, e1622-e1627
26. Simmons, J., Cookman, L., Kang, C., and Skinner, C. (2011) Three cases of "spice" exposure Clin. Toxicol. 49, 431-433
27. Young, A. C., Schwarz, E., Medina, G., Obafemi, A., Feng, S.-Y., Kane, C., and Kleinschmidt, K. (2012) Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation Am. J. Emerg. Med. 30, 1320.e5-1320.e7
28. Heath, T. S., Burroughs, Z., Thompson, A. J., and Tecklenburg, F. W. (2012) Acute intoxication caused by a synthetic cannabinoid in two adolescents J. Pediatr. Pharmacol. Ther. 17, 177-181
29. Schneir, A. and Baumbacher, T. (2012) Convulsions associated with the use of a synthetic cannabinoid product J. Med. Toxicol. 8, 62-64
30. Harris, C. R. and Brown, A. (2013) Synthetic cannabinoid intoxication: A case series and review J. Emerg. Med. 44, 360-366
31. Karch, S. (2006) Cannabis and cardiotoxicity Forensic Sci. Med. Pathol. 2, 13-18
32. Schneir, A. B., Cullen, J., and Ly, B. T. (2011) Spice" girls: Synthetic cannabinoid intoxication J. Emerg. Med. 40, 296-299
33. Every-Palmer, S. (2010) Warning: Legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals Addiction 105, 1859-1860
34. Every-Palmer, S. (2011) Synthetic cannabinoid JWH-018 and psychosis: An explorative study Drug Alcohol Depend. 117, 152-157
35. Brakoulias, V. (2012) Products containing synthetic cannabinoids and psychosis Aust. N. Z. J. Psychiatry 46, 281-282
36. Wells, D. L. and Ott, C. A. (2011) The "new" marijuana Ann. Pharmacother. 45, 414-417
37. Hutter, M., Broecker, S., Kneisel, S., and Auwärter, V. (2012) Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques J. Mass Spectrom. 47, 54-65
38. Brents, L. K., Reichard, E. E., Zimmerman, S. M., Moran, J. H., Fantegrossi, W. E., and Prather, P. L. (2011) Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity PLoS One 6, e21917
39. Seely, K. A., Brents, L. K., Radominska-Pandya, A., Endres, G. W., Keyes, G. S., Moran, J. H., and Prather, P. L. (2012) A major glucuronidated metabolite of JWH-018 is a neutral antagonist at CB1 receptors Chem. Res. Toxicol. 25, 825-827
40. Brents, L. K., Gallus-Zawada, A., Radominska-Pandya, A., Vasiljevik, T., Prisinzano, T. E., Fantegrossi, W. E., Moran, J. H., and Prather, P. L. (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochem. Pharmacol. 83, 952-961
41. Jerry, J., Collins, G., and Streem, D. (2012) Synthetic legal intoxicating drugs: The emerging 'incense' and 'bath salt' phenomenon Clev. Clin. J. Med. 79, 258-264
42. Lindigkeit, R., Boehme, A., Eiserloh, I., Luebbecke, M., Wiggermann, M., Ernst, L., and Beuerle, T. (2009) Spice: A never ending story? Forensic Sci. Int. 191, 58-63
43. Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., and Goda, Y. (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product Forensic Toxicol. 27, 61-66
44. Dresen, S., Ferreirós, N., Pütz, M., Westphal, F., Zimmermann, R., and Auwärter, V. (2010) Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds J. Mass Spectrom. 45, 1186-1194
45. Hudson, S., Ramsey, J., King, L., Timbers, S., Maynard, S., Dargan, P. I., and Wood, D. M. (2010) Use of high-resolution accurate mass spectrometry to detect reported and previously unreported cannabinomimetics in "herbal high" products J. Anal. Toxicol. 34, 252-260
46. Ernst, L., Schiebel, H.-M., Theuring, C., Lindigkeit, R., and Beuerle, T. (2011) Identification and characterization of JWH-122 used as new ingredient in ″Spice-like″ herbal incenses Forensic Sci. Int. 208, e31-e35
47. 35S]GTPγS binding assays Forensic Toxicol. 29, 132-141
48. Nakajima, J. i., Takahashi, M., Seto, T., and Suzuki, J. (2011) Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the internet Forensic Toxicol. 29, 51-55
49. Nakajima, J.-i., Takahashi, M., Seto, T., Kanai, C., Suzuki, J., Yoshida, M., and Hamano, T. (2011) Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1 H -indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the internet Forensic Toxicol. 29, 95-110
50. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2011) Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products Forensic Toxicol. 29, 25-37
51. Uchiyama, N., Kikura-Hanajiri, R., and Goda, Y. (2011) Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB1 and CB2 receptors Chem. Pharm. Bull. 59, 1203-1205
52. Kneisel, S., Bisel, P., Brecht, V., Broecker, S., Müller, M., and Auwärter, V. (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures Forensic Toxicol. 30, 126-134
53. Kneisel, S. and Auwaerter, V. (2012) Analysis of 30 synthetic cannabinoids in serum by liquid chromatography-electrospray ionization tandem mass spectrometry after liquid-liquid extraction J. Mass Spectrom. 47, 825-835
54. Nakajima, J.-i., Takahashi, M., Seto, T., Yoshida, M., Kanai, C., Suzuki, J., and Hamano, T. (2012) Identification and quantitation of two new naphthoylindole drugs-of-abuse, (1-(5-hydroxypentyl)-1 H -indol-3-yl) (naphthalen-1-yl)methanone (AM-2202) and (1-(4-pentenyl)-1 H -indol-3-yl)(naphthalen-1-yl)methanone, with other synthetic cannabinoids in unregulated ″herbal″ products circulated in the Tokyo area Forensic Toxicol. 30, 33-44
55. Takahashi, K., Uchiyama, N., Fukiwake, T., Hasegawa, T., Saijou, M., Motoki, Y., Kikura-Hanajiri, R., and Goda, Y. (2013) Identification and quantitation of JWH-213, a cannabimimetic indole, as a designer drug in a herbal product Forensic Toxicol. 31, 145-150
56. Westphal, F., Sönnichsen, F. D., and Thiemt, S. (2012) Identification of 1-butyl-3-(1-(4-methyl)naphthoyl)indole in a herbal mixture Forensic Sci. Int. 215, 8-13
57. Zuba, D. and Byrska, B. (2013) Analysis of the prevalence and coexistence of synthetic cannabinoids in "herbal high" products in Poland Forensic Toxicol. 31, 21-30
58. Grigoryev, A., Kavanagh, P., and Melnik, A. (2012) The detection of the urinary metabolites of 3-[(adamantan-1-yl)carbonyl]-1-pentylindole (AB-001), a novel cannabimimetic, by gas chromatography-mass spectrometry Drug Test. Anal. 4, 519-524
59. Jankovics, P., Váradi, A., Tölgyesi, L., Lohner, S., Németh-Palotás, J., and Balla, J. (2012) Detection and identification of the new potential synthetic cannabinoids 1-pentyl-3-(2- iodobenzoyl)indole and 1-pentyl-3-(1-adamantoyl)indole in seized bulk powders in Hungary Forensic Sci. Int. 214, 27-32
60. Kneisel, S., Westphal, F., Bisel, P., Brecht, V., Broecker, S., and Auwärter, V. (2012) Identification and structural characterization of the synthetic cannabinoid 3-(1-adamantoyl)-1-pentylindole as an additive in 'herbal incense' J. Mass Spectrom. 47, 195-200
61. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2012) Identification of two new-type synthetic cannabinoids, N -(1-adamantyl)-1- pentyl-1 H -indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1 H -indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products Forensic Toxicol. 30, 114-125
62. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R., and Goda, Y. (2013) URB-754: A new class of designer drug and 12 synthetic cannabinoids detected in illegal products Forensic Sci. Int. 227, 21-32
63. Frost, J. M., Dart, M. J., Tietje, K. R., Garrison, T. R., Grayson, G. K., Daza, A. V., El-Kouhen, O. F., Yao, B. B., Hsieh, G. C., Pai, M., Zhu, C. Z., Chandran, P., and Meyer, M. D. (2010) Indol-3-ylcycloalkyl ketones: Effects of N1 substituted indole side chain variations on CB2 cannabinoid receptor activity J. Med. Chem. 53, 295-315
64. Makriyannis, A. and Deng, H. (2001) Preparation of cannabimimetic indole derivatives with cannabinoid CB1 or CB2 receptor binding affinity. Patent WO2001028557A1.
65. Makriyannis, A. and Deng, H. (2002) Preparation of CB2 cannabinoid receptor-selective cannabimimetic aminoalkylindoles, particularly (piperidinylmethyl)- and (morpholinylmethyl)indoles, and their use. Patent WO2002060447A1.
66. Makriyannis, A. and Deng, H. (2007) Receptor selective cannabimimetic aminoalkylindoles. Patent US20070243134A1.
67. Pasquini, S., De Rosa, M., Pedani, V., Mugnaini, C., Guida, F., Luongo, L., De Chiaro, M., Maione, S., Dragoni, S., Frosini, M., Ligresti, A., Di Marzo, V., and Corelli, F. (2011) Investigations on the 4-quinolone-3-carboxylic acid motif. 4. Identification of new potent and selective ligands for the cannabinoid type 2 receptor with diverse substitution patterns and antihyperalgesic effects in mice J. Med. Chem. 54, 5444-5453
68. Pasquini, S., Mugnaini, C., Ligresti, A., Tafi, A., Brogi, S., Falciani, C., Pedani, V., Pesco, N., Guida, F., Luongo, L., Varani, K., Borea, P. A., Maione, S., Di, M. V., and Corelli, F. (2012) Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3- yloxoacetamides, and indol-3-ylcarboxamides: Potent and selective CB2 cannabinoid receptor inverse agonists J. Med. Chem. 55, 5391-5402
69. Okauchi, T., Itonaga, M., Minami, T., Owa, T., Kitoh, K., and Yoshino, H. (2000) A general method for acylation of indoles at the 3-position with acyl chlorides in the presence of dialkylaluminum chloride Org. Lett. 2, 1485-1487
70. Liang, G., Choi-Sledeski, Y. M., Poli, G., Chen, X., Shum, P., Minnich, A., Wang, Q., Tsay, J., Sides, K., Cairns, J., Stoklosa, G., Nieduzak, T., Zhao, Z., Wang, J., and Vaz, R. J. (2010) A conformationally constrained inhibitor with an enhanced potency for β-tryptase and stability against semicarbazide-sensitive amine oxidase (SSAO) Bioorg. Med. Chem. Lett. 20, 6721-6724
71. Knapman, A., Santiago, M., Du, Y. P., Bennallack, P. R., Christie, M. J., and Connor, M. (2013) A continuous, fluorescence-based assay of μ-opioid receptor activation in AtT-20 cells J. Biomol. Screening 18, 269-276
72. Mackie, K., Lai, Y., Westenbroek, R., and Mitchell, R. (1995) Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor J. Neurosci. 15, 6552-6561
73. 8-THC during acute and chronic administration to conscious rats Pharmacology 15, 65-72
74. 9-tetrahydrocannabinol by clomipramine in the rat Br. J. Pharmacol. 63, 267-273
75. Smirnov, M. S. and Kiyatkin, E. A. (2008) Behavioral and temperature effects of delta 9-tetrahydrocannabinol in human-relevant doses in rats Brain Res. 1228, 145-160
76. Wiley, J. L., Marusich, J. A., Martin, B. R., and Huffman, J. W. (2012) 1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice Drug Alcohol Depend. 123, 148-53
77. Weng, Y., Sun, S., Park, J., Ye, S., Weil, M. H., and Tang, W. (2012) Cannabinoid 1 (CB1) receptor mediates WIN55, 212-2 induced hypothermia and improved survival in a rat post-cardiac arrest model Resuscitation 83, 1145-1151
78. Järbe, T. C., Tai, S., LeMay, B., Nikas, S., Shukla, V., Zvonok, A., and Makriyannis, A. (2012) AM2389, a high-affinity, in vivo potent CB1-receptor-selective cannabinergic ligand as evidenced by drug discrimination in rats and hypothermia testing in mice Psychopharmacology 220, 417-426
79. Blaazer, A. R., Lange, J. H. M., van der Neut, M. A. W., Mulder, A., den Boon, F. S., Werkman, T. R., Kruse, C. G., and Wadman, W. J. (2011) Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure-activity relationships, physicochemical properties and biological activity Eur. J. Med. Chem. 46, 5086-5098
80. Bruker. (2011) Apex2 suite of programs, Bruker AXS Inc., Madison, WI.
81. Sheldrick, G. M. (2008) A short history of SHELX Acta Crystallogr., Sect. A A64, 112-122-122